within Pharmacolibrary.Drugs.ATC.G;

model G03FA01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.5,
    Cl             = 1.6666666666666667e-05,
    adminDuration  = 600,
    adminMass      = 1 / 1000000,
    adminCount     = 1,
    Vd             = 0.004,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>NorethisteroneAndEstrogen</td></tr><tr><td>ATC code:</td><td>G03FA01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Norethisterone and estrogen are combined hormonal preparations used for hormone replacement therapy (HRT) in postmenopausal women and previously also in contraception. Norethisterone is a synthetic progestogen, while estrogen in such combinations is commonly estradiol or ethinylestradiol. These combinations alleviate menopausal symptoms and prevent osteoporosis. Such combined HRT regimens are approved and used in many countries today.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adult women after oral administration, based on typical literature values for norethisterone and estradiol or ethinylestradiol separately, as no published studies provide a combined PK model for the combination product.</p><h4>References</h4><ol><li><p>Vose, CW, et al., &amp; Serlin, MJ (1979). Bioavailability and pharmacokinetics of norethisterone in women after oral doses of ethynodiol diacetate. <i>Contraception</i> 19(2) 119–127. DOI:<a href=\"https://doi.org/10.1016/s0010-7824(79)80024-4\">10.1016/s0010-7824(79)80024-4</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/428229/\">https://pubmed.ncbi.nlm.nih.gov/428229</a></p></li><li><p>Goldzieher, JW (1990). Selected aspects of the pharmacokinetics and metabolism of ethinyl estrogens and their clinical implications. <i>American journal of obstetrics and gynecology</i> 163(1 Pt 2) 318–322. DOI:<a href=\"https://doi.org/10.1016/0002-9378(90)90575-r\">10.1016/0002-9378(90)90575-r</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2196804/\">https://pubmed.ncbi.nlm.nih.gov/2196804</a></p></li><li><p>Garza-Flores, J, et al., &amp; Perez-Palacios, G (1991). Long-acting hormonal contraceptives for women. <i>The Journal of steroid biochemistry and molecular biology</i> 40(4-6) 697–704. DOI:<a href=\"https://doi.org/10.1016/0960-0760(91)90293-e\">10.1016/0960-0760(91)90293-e</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/1958567/\">https://pubmed.ncbi.nlm.nih.gov/1958567</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial generated model</li></ul></body></html>"
  ));
end G03FA01;
